Clinical trial · Observational
QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.
Quality of Life of Women With Hormone Receptor-Positive Metastatic Breast Cancer Treated in the First-line Setting: Comparison Between Public and Private Institutions.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assess the quality of life in patients with hormone receptor positive, human epidermal growth factor receptor-type 2 negative metastatic breast cancer treated in first line (patients with new metastasis or recurrence during adjuvant endocrine therapy): comparison between public and private institutions. The hypothesis to be evaluated is that patients treated in private institutions have a better quality of life when compared to patients treated in public institutions.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm Female | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quality of Life | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Hospital Beneficência Portuguesa de SP - BP1
- description
- Patients from private institutions.
- interventionNames
- Other: Quality of Life
- label
- Hospital Pérola Byington - HPB2
- description
- Patients from public institutions.
- interventionNames
- Other: Quality of Life
Primary outcomes (2)
- measure
- Assess the quality of life
- timeFrame
- Baseline
- description
- Assess the quality of life using the EORTC-QLQ-C30 (EORTC Quality of Life Questionnaire)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who agree to participate by signing a document of free and informed consent (ICF), indicating that the research participant was informed about all relevant aspects of the study; * Female patients ≥ 18 years of age; * Patients diagnosed with hormone receptor positive, human epidermal growth factor receptor-type 2 -negative metastatic breast cancer; in first-line treatment (metastatic de novo disease or patients with recurrence during adjuvant endocrine therapy). * First-line treatment can be considered as cytotoxic chemotherapy, isolated endocrine therapy or endocrine therapy in combination with 4/6 cyclin inhibitors. * Patients on treatment for at least three (3) months and no more than eighteen (18) months. * Have performance status Eastern Cooperative Oncology Group (ECOG scale) of 0-2. * Do not present other concomitant neoplasms. Exclusion Criteria: * Patients who refuse to participate. * Illiterate patients, with low levels of education or cognitive deficits that make it difficult to answer the questions of the data collection instrument. * Patients with life expectancy \<3 months. * Treatment with any product under investigation during the last 28 days.
References
Publications (0)
Data not yet available